---
title: "Panlong Pharmaceutical: In the first half of 2025, the net profit was 60.1352 million yuan, a year-on-year increase of 0.81%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254838140.md"
description: "Panlong Pharmaceutical announced that in the first half of 2025, the operating revenue was 574 million yuan, a year-on-year increase of 26.06%. The net profit was 60.1352 million yuan, a year-on-year increase of 0.81%. The company plans to distribute a cash dividend of 1 yuan for every 10 shares based on a total of 106 million shares to all shareholders"
datetime: "2025-08-27T13:50:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254838140.md)
  - [en](https://longbridge.com/en/news/254838140.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254838140.md)
generator: "portal-rs"
---

# Panlong Pharmaceutical: In the first half of 2025, the net profit was 60.1352 million yuan, a year-on-year increase of 0.81%

Panlong Pharmaceutical announced that in the first half of 2025, operating revenue reached 574 million yuan, a year-on-year increase of 26.06%. Net profit was 60.1352 million yuan, a year-on-year increase of 0.81%. The company plans to distribute a cash dividend of 1 yuan for every 10 shares based on a total of 106 million shares to all shareholders

### Related Stocks

- [002864.CN](https://longbridge.com/en/quote/002864.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [This Former Small-Cap Darling Is in Freefall, But I Like the Stock Here](https://longbridge.com/en/news/296374899.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [Is it still protectionism when a national champion is part foreign-owned?](https://longbridge.com/en/news/296408762.md)
- [OncoZenge registers 772,797 shares in directed issue after SEK 5 million payment from Sichuan Yangtian](https://longbridge.com/en/news/296607308.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**